A Candida albicans cytoplasmic antigen enzyme immunoassay (CACP antigen EIA) was developed with antibodies raised against antigens prepared from yeast cells grown under standardized growth conditions. The C. albicans components reactive in the EIA were shown to be predominantly proteins with associated carbohydrates. Denaturing gel electrophoresis revealed the presence of five major CACP proteins with molecular weights between 36,000 and 44,000. The clinical usefulness of the CACP EIA was evaluated by retrospective blinded measurement of 89 serum samples from 31 granulocytopenic patient episodes. Twiceweekly surveillance cultures, sequential serum samples (approximately once per week or with change of the clinical course), and standard diagnostic criteria of fungal infection were used to categorize patients. The sensitivity and specificity of the CACP assay on the basis of serum samples were 82 and 100%o, respectively (67 and 100% on the basis of patient episodes). The positive and negative predictive values were 100 and 97% for serum (100 and 93% for patient episodes). By comparison, the CANDTEC assay had low sensitivity (33%) and poor positive predictive values (50%). The CACP EIA may be a useful test suitable for further evaluation as a method for the diagnosis of invasive Candida infection in neutropenic cancer patients.
Detection of Candida antigenemia, particularly in neutropenic cancer patients, may be an important adjunct to the diagnosis and treatment of invasive fungal infection. Presently, definitive diagnosis of candidiasis is dependent upon tissue histology and cultures or positive blood cultures. Both methods, while specific, are insensitive for the diagnosis of deep fungal infection. In the absence of practical diagnostic methods, patients are often treated empirically with antifungal agents should broad-spectrum antibacterial therapy fail to resolve apparent infectious episodes. However, the response to empiric antifungal therapy is difficult to assess. Causes of persistent fever in the neutropenic host include poorly responsive bacterial infection, bacterial superinfection, viral infection, fungal infection, underlying disease, blood products, and drug fever either singly or in combination. Therefore, laboratory diagnostic support would be invaluable in deciding upon treatment for these patients.
Neutropenic and immunosuppressed patients may not mount a significant antibody response to candidal antigens despite deep tissue infection. Candidal antibody tests have been poor predictors of invasive disease. In the past decade, the detection of fungal antigens has been proposed as a better predictor of infection in these patients. A number of methods have been developed to address this issue (6, 11, 17, 18, 26, 28, 29, 40, 44, 45, (48) (49) (50) . Three commercial assays are available for detection of Candida antigens (13, 14, 22, 24, 37, 42) . One of these (LA-CADS; Immunomycologics Inc., Norman, Okla.)
has not been subjected to a controlled clinical evaluation. The CANDTEC assay (Ramco Laboratories Inc., Houston, Tex.) has been shown to be relatively insensitive (30 to 50%) in Sabouraud's dextrose broth contained in a 4-liter Ehrlenmeyer flask. The cultures were incubated in a shaking controlledtemperature incubator at 120 rpm at 30°C until the late-log phase of growth (11 to 12 h). The cells were collected by centrifugation for 10 min at 2,000 x g at 4°C and resuspended in an equal volume of deionized double-distilled H20. The cells were recentrifuged and, after an additional wash cycle, were resuspended in 20 ml of double-distilled H20. The resulting slurry was passed five times at 4°C and 69,000 kPa through a French pressure cell (American Instrument Co., Silver Spring, Md.). Cell disruption was estimated at 95% as determined by phase-contrast microscopy. Unbroken cells and cellular debris were removed by centrifugation at 12 ,600 x g at 4°C for 30 min. Antigens in this supernatant are referred to as CACP antigens. Antigens in the supernatant after ultracentrifugation at 100,000 x g at 4°C for I h are referred to as Ultra CACP antigens. Protein Electrophoresis was initiated at 100 V and increased to 125 V once the tracking dye had entered the separating gel. After the tracking dye had exited the separating gel, the gel was removed and stained with Coomassie blue R-250 (Sigma).
Two-dimensional SDS-PAGE was performed according to the method of O'Farrell (38) . Protein samples were diluted 1:3 in sample buffer (9.5 M urea (32a) . For the purpose of expressing the density of fungal colonization at each site for each neutropenic episode, the mean-plus count of fungal colonization was determined. Urine samples were cultured with 0.01-and 0.001-ml loops.
Patient management. Patients were hospitalized in single isolation rooms; diet consisted of normal hospital food with the exclusion of salads. Gut decontamination in afebrile patients included trimethoprim-sulfamethoxazole or nalidixic acid (8) . Oral antifungal therapy with nystatin (106 U every 6 h) was added for clinically apparent mucosal infection (9) . At the onset of fever (>38.5°C for more than 12 h or chills, rigors, and fever >39°C), oral antibacterial gut decontamination was discontinued, and empiric intravenous antimicrobial therapy was started. Antibiotics included ticarcillin, moxalactam, or aztreonam, plus an aminoglycoside; gram-positive coverage with vancomycin or cloxacillin was added at the discretion of the infectious disease service. Intravenous amphotericin B (0.6 to 1.0 mg/kg/day-maximum 60 mg/day) was added if patients failed to respond to 4 to 10 days of antibacterial therapy.
For the purposes of analysis, the patients were divided into four subgroups on the basis of clinical and microbiological criteria. Group I included patients who were not colonized by Candida species, were less likely to be at risk for disseminated candidiasis on the basis of previous epidemiologic studies (9, 15), did not develop criteria for disseminated candidiasis, or had documented nonfungal infection. Group II included patients who became colonized by Candida species in surveillance cultures but who had documented nonfungal infection or had autopsy evidence excluding fungal infection. Group III included patients clinically suspected to have fungal infection on the basis of their failure to respond to antibacterial therapy and their response to empiric amphotericin B and/or coincident resolution of neutropenia with or without the isolation of fungi. Group IV included patients with documented fungal infection on the basis of blood cultures, tissue biopsies, or postmortem examination.
Control serum samples were obtained from six healthy laboratory staff, 30 infant serum samples, and pooled normal human sera. None of these gave positive responses in the EIA antigen assay. Although the CACP antigen EIA was capable of detecting as little as 5 ng of Candida antigen, the threshold concentration for positivity of patient samples was conservatively determined to be 150 ng/ml, since the most linear portion of the standard curve began at this antigen concentration, and a more precise computerized interpolation of results from patients' sera was possible.
The CANDTEC assay was used according to the manufacturer's instructions in serial twofold dilutions beginning at ratios of 1:2 to 1:16. Positive and negative control sera were included with each test, and a positive result was taken to be a titer of .1:4 according to the manufacturer's recommendations. The sensitivity and specificity of these assays were developed with methods outlined by Galen and Gambino (23 One-and two-dimensional SDS-PAGE of CACP antigens. Five major proteins with molecular weights of 36,000, 38,000, 41,000, 42,000, and 44,000 (Fig. 1, lanes A, C, F , and G) were observed in the C. albicans strains tested, including ATCC 31353. These proteins were enriched in Ultra CACP antigen preparations (Fig. 1, lanes B and D) . Analysis of cytoplasmic antigens from C. parapsilosis 64538 revealed three major proteins in the same molecular weight range (Fig. 1, lane E) . Cytoplasmic antigens of C. tropicalis 89724 showed only one major protein (molecular weight, 36,000) in this size range (data not shown). The five major CACP proteins of C. albicans 60553 are shown by two-dimensional SDS-PAGE in Fig. 2 Figure 5 shows the clinical course of patient 26 and how this correlated with results obtained with the CACP antigen EIA. He was admitted with maxillary sinusitis and fever, responded to amoxicillin therapy, but became heavily colonized in the oropharynx and feces with C. albicans (Table 1) . He developed pyrexia on day 10, failed to respond to broad-spectrum antibiotic therapy, and was subsequently treated with amphotericin B. He temporarily improved but developed a persisting febrile illness unresponsive to either modified antibacterial or antifungal therapy. The amphotericin B therapy was associated with a reduction in CACP antigen concentrations to <50 ng/ml, but the patient subsequently died without resolution of his fever. C. albicans was identified in postmortem samples from the liver and spleen. Aspergillus fumigatus was isolated from the lungs.
Patient 27 had acute stem cell leukemia and severe persistent marrow aplasia with granulocyte counts of less than 0.1 x 109/liter until the time of death at day 38. She presented with fever, a pulmonary infiltrate, and an Escherichia coli urinary tract infection. Both the CACP and CANDTEC assay were negative on presentation. She was not colonized with fungi during the initial 10 days of hospitalization. However, on moxalactam-ticarcillin therapy, she developed multiple-site colonization with C. tropicalis. She was treated with high-dose co-trimoxazole, ticarcillin, and gentamicin for an Acinetobacter calcoaceticus var. iwofi pneumonitis. However, with progressive deterioration in her pulmonary status, a transbronchial brush biopsy was performed. This showed no fungi, but low counts of Acinetobacter sp. were recovered. The serum CACP was positive at 380 ng/ml at that time, and the CANDTEC assay was positive at 1:8. She subsequently succumbed despite added empiric amphotericin B and further antibiotics for a terminal Staphylococcus epidermidis bacteremia. Autopsy showed C. tropicalis in the lung and spleen and Acinetobacter sp. in the lung.
Patient 28 had a fever of unknown origin treated with moxalactam-ticarcillin and showed a temporary and partial reduction in fever from 39°C to 37.6°C between days 5 and 8 of antibiotic therapy. The CACP titer was 217 ng/ml at presentation, with a negative CANDTEC assay. Fever recurred on day 9 and persisted despite a change in antibiotics to cefazolintobramycin and vancomycin. Isoniazid was also added because of possible reactivation of Mycobacterium tuberculosis infection. The CACP titer was 257 ng/ml, and the CANDTEC assay was negative on day 11. Fever temporarily improved over a week, but the patient developed high-grade fever (39 to 40°C) and developed C. parapsilosis fungemia on days 25 (one of two sets) and 28 (one of two sets with S. epidermidis also). On day 26, the CACP titer was negative at 65 ng/ml, and the CAND-TEC assay was negative. Amphotericin B therapy was begun on day 28, and he survived the fungal infection with resolution of the granulocytopenia by day 33, at which time the CACP assay was nonreactive (<50 ng/ml). For all sera, CANDTEC assay results were negative or 1:4, with no samples reactive at a 1:2 dilution. The sensitivity, specificity, and predictive values of the CACP antigen EIA and CANDTEC assay on the basis of the clinical parameters in these patients are shown in Table 2 . The sensitivity of the CACP antigen EIA was 67%, with a specificity of 100% and a positive predictive value of 100%. The CAND-TEC assay had a sensitivity of 33% and a specificity of 92%, with a positive predictive value of 50%. If individual serum samples were used to calculate the data, the sensitivity of the CACP antigen EIA rose to 82% without affecting specificity or positive predictive values.
DISCUSSION
The laboratory diagnosis of invasive candidiasis remains a problem (16) . Many patients at high risk for developing invasive candidiasis are severely immunosuppressed and do not mount a significant humoral response (19, 21) . Assays detecting antibodies to Candida-specific antigens are of little diagnostic value. Because of this, laboratory diagnosis of invasive candidiasis has shifted to detecting Candida antigens. Antigen assays have concentrated on mannan, since mannan antigenemia was thought to be specific for invasive candidiasis (32) . However, it has also been suggested that detection of Candida cytoplasmic antigens may also be useful in diagnosing invasive candidiasis (19, 20) .
Microbiologic tests for diagnosing invasive candidiasis show a poor positive predictive value of surface colonization data, infrequent documentation of fungemia, and lack of clinical parameters suggesting fungal infection. Furthermore, the difficulty of obtaining specimens from various tissues to recover fungi during life complicates diagnosis. The response or lack thereof to empiric amphotericin B is an uncertain therapeutic trial for diagnosing fungal infection. Decreasing postmortem rates used to verify diagnoses further obfuscate evaluation of clinical studies.
In this study, candidal cytoplasmic antigens were produced under standardized growth conditions and with a simplified preparative procedure in order to minimize antigen variability. Analysis of the CACP antigens by one-and two-dimensional SDS-PAGE revealed the presence of five major proteins ranging in size from 36,000 to 44,000, with pls ranging from approximately 6.5 to 8.5. Whether any of these five proteins equates to the C. albicans proteins described by others is unclear. A C. albicans protein with a molecular weight of approximately 45,000 has been described (4, 35, 47) , but molecular weights have varied considerably between reports. This variability may be due to differences in the growth phase of the organism and differences in how the cytoplasmic antigens were prepared (35, 46) . Strockbine et al. (46) described a C. albicans cytoplasmic protein having a molecular weight of approximately 36,000 and reported that limited proteolysis of three proteins (including a protein with a molecular weight of 36,000) immunoprecipitated by a monoclonal antibody indicated a similarity in primary sequence. Whether any of our CACP antigens are similar remains to be determined. The CACP antigen preparations consist of proteins with associated carbohydrate, as shown by the effects of heat, protease, and periodate upon reactivity in the CACP antigen EIA. Heating at 56°C partially abolished CACP antigen reactivity in the EIA, and heating at 80°C completely abolished it, suggesting protein is responsible for much of the EIA reactivity. The partial loss of CACP antigen reactivity following periodate treatment indicated that carbohydrate antigens are also present. Our CACP antigen preparations were not subjected to concanavalin A column chromatography, which others have done in the preparation of cytoplasmic antigen (25, 47) . Chromatography on concanavalin A would have resulted in the removal not only of cell wall debris but also of cytoplasmic glycoproteins, some of which may be important diagnostically.
Despite the same conditions being used to prepare cytoplasmic antigens from C. parapsilosis, these antigens did not react appreciably in the CACP antigen EIA. Analysis of additional strains would have been helpful, since there may be strain variation in cytosol antigens. However, since invasive disease caused by C. parapsilosis is uncommon, the diagnostic utility of the assay may not be severely impaired (7). Burnie et al. (12) found by immunoblotting with both C. albicans yeast-and mycelium-specific antiserum that the cross-reactivity with C. parapsilosis was greater than that with C. tropicalis, which we found to be reversed in the present study. Burnie et al. (12) attributed the greater cross-reactivity to mannan, but they speculated that proteins with molecular weights greater than 33,000 were also involved. This suggestion appears to be VOL. 32, 1994 The sensitivity and specificity of the CACP assay indicate that patients who are consistently negative for CACP antigen in blood, whether or not they are colonized with C. albicans, are at low risk of development of invasive infection during their periods of neutropenia. On the basis of sequential sampling of patients at high risk for developing invasive candidiasis, the sensitivity and specificity of the CACP antigen EIA were 67% (patient episodes) and 82% (serum samples), respectively. The positive predictive value of the CACP antigen EIA was 99 to 100%, compared with 50% for the CANDTEC assay. The observations with patient 27 (Table 1) show that C. tropicalis cytoplasmic antigens may also be detected by this assay (34) .
In summary, the clinical utility of a Candida cytoplasmic antigen assay was evaluated blindly with 31 neutropenic patient episodes. The results are clearly superior to those with the CANDTEC assay, but due to the limited number of patients tested, it will be important to further evaluate this assay in a prospective fashion. Several variables of importance in the future evaluation of EIA fungal antigen assays were identified during this study.
